Mobile

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

Mise à jour : Il y a 4 ans
Référence : NCT01464112

Femme et Homme

  • | Pays :
  • France
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The purpose of this study is to evaluate the safety and tolerability and to establish the maximum tolerated dose of JNJ-26481585 combined with VELCADE and dexamethasone.

Critère d'inclusion

  • Multiple myeloma

Liens